Brief: X4 Pharmaceuticals And Taiba Rare Announce Exclusive Agreement For The Distribution And Commercialization Of Xolremdi® (Mavorixafor) In Whim Syndrome In Select Middle East Countries
19/02/2025 15:00
Feb 19 (Reuters) - X4 Pharmaceuticals Inc XFOR.O :
* X4 PHARMACEUTICALS AND TAIBA RARE ANNOUNCE EXCLUSIVE
AGREEMENT
FOR THE DISTRIBUTION AND COMMERCIALIZATION OF XOLREMDI®
(MAVORIXAFOR) IN WHIM SYNDROME IN SELECT MIDDLE EAST COUNTRIES
Source text: ID:nGNXbtkfPy
Further company coverage: XFOR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on X4 Pharmaceuticals
See all newsBrief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
X4 Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: X4 Pharmaceuticals Q2 Operating Expenses USD 25.197 Million
X4 Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule